Patients with AML with FLT3 co-mutations are excluded due to their increased risk of relapse seen in both intensively and non-intensively treated patients and the availability of effective targeted treatments, such as midostaurin, quizartinib [16–18]. Here, FLT3 is linked to acute myeloid leukemia.